No Data
No Data
Hong Kong stocks closed (05.23) | Hang Seng Index closed down 1.7%, fell to Wanjiu Customs Network, non-ferrous stocks fell by 5% Alibaba - SW (09988) plummeted 5%
Hong Kong stocks fell under pressure throughout the day. The Hang Seng Index fell below the 19,000 mark. At one point, the Hang Ke Index fell close to 3% at the end of the session. At the close, the Hang Seng Index fell 1.7%, or 326.89 points, to 18868.71 points.
HBM Holdings Unit, AstraZeneca Sign License, Option Agreement for Targeted Cancer Treatment; Shares Rise 16%
HBM Holdings (HKG:2142) subsidiary Nona Biosciences (Suzhou) signed a license and option agreement with AstraZeneca to collaborate on preclinical monoclonal antibodies for targeted cancer therapies, a
Nona Biosciences: Announces Global License and Option Agreement With AstraZeneca for Monoclonal Antibody to Be Developed Into Novel Tumor Targeted Therapies
Nona Biosciences: Announces Global License and Option Agreement With AstraZeneca for Monoclonal Antibody to Be Developed Into Novel Tumor Targeted Therapies
Nona Biosciences: Shall Receive $19M Upon Completion of Transaction, Is Eligible to Receive Additional $10M in Potential Near-Term Milestone Payments and Up to $575M >2142.HK
Nona Biosciences: Shall Receive $19M Upon Completion of Transaction, Is Eligible to Receive Additional $10M in Potential Near-Term Milestone Payments and Up to $575M >2142.HK
Nona Biotech and AstraZeneca reach global licensing and options agreement for monoclonal antibody project
Accelerating the development of innovative tumor-targeted therapies, Cambridge, Massachusetts, May 23, 2024/PRNewswire/ -- Nona Biotech (a wholly-owned subsidiary of Platinum Pharmaceuticals), an international innovative biotechnology company dedicated to cutting-edge technological innovation and providing partners with complete Idea to IND (I to ITM) services covering target verification and next-generation biomacromolecule drug discovery to pre-clinical development, announced today that it has reached a licensing agreement with AstraZeneca on a preclinical monoclonal antibody project to accelerate the development of tumor-targeted therapies. Under the agreement, Nona Biotech is trading
Harbour BioMed Pharmaceutical-B (02142.HK): Concludes licensing and option agreement with AstraZeneca for novel tumor-targeted therapies
On May 23, Gelonghui Pharmaceutical-B (02142.HK) announced that Nona Biotech (Suzhou) Co., Ltd. (“Nona Biotech”), a wholly-owned subsidiary of the company, has entered into a licensing and option agreement with AstraZeneca (LSE/ STO/ NASDAQ: AZN) (“AstraZeneca”) for preclinical monoclonal antibodies used to create targeted cancer therapies. According to the agreement, Nona Biotech will: collect an advance payment of $19 million upon completion of the transaction; collect $10 million in recent milestone payments; and collect up to 5.7 when specific development, regulatory and commercial milestones are completed
No Data